This guide does not gloss over anything
Drugs 1 , 347354 (2000)
doi: 10.3389/fcell.2025.1737456 Received 01 November 2025 Revised 14 December 2025 Accepted 22 December 2025 Published 12 January 2026 Volume 13 - 2025 Edited by Silvia Masciarelli, Sapienza University of Rome, Italy Reviewed by Xuchang Zhou, The First Affiliated Hospital of Xiamen University, China Weibei Sheng, Peking University, China Updates Copyright 2026 Zhang, Li, Yang and Yang
Approved Semaglutide Peptide (CAS: 910463-68-2) Based Medications Benefits of Semaglutide Peptide (NN9535) Compared to Other GLP-1 Analogues (e.g., Liraglutide, Dulaglutide) Extended half-life (7 days): Allows convenient once-weekly dosing, unlike native GLP-1 or other analogues (e.g., liraglutide) that require more frequent administration
Administration of the interacting drugs was timed so that Cmax of liraglutide (8-12 h) would coincide with the absorption peak of the co-administered drugs